Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer and BioNTech had filed their lawsuit in September 2022 over patents relating to messenger RNA (mRNA) technology,
Pfizer secures patent win at UK High Court in RSV vaccine race
The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving Pfizer, as both companies battle to become the first to launch an RSV vaccine on the UK market.
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV vaccine. The ruling is part of ongoing litigation between the two drugmakers over their respective RSV vaccines.
Pfizer CEO’s Job Is at Risk. A Shot of Discipline Could Help.
As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Meet Jeff Smith, the hedge-fund investor taking on Pfizer
Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...
Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential
Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...
Watch These Pfizer Price Levels as Stock Gains After Report of Starboard Taking Stake
Pfizer shares have gained ground since a report over the weekend said that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes. Monitor ...
Pfizer’s Hold Rating: Balancing Activist Influence and Growth Challenges
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...
Pfizer: A Strong Product Pipeline Could Lead To Significant Upside
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...